Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07181161 · ClinicalTrials.gov registry record · Phase 1

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

A Phase 1 study of Metastatic Prostate Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
177
Enrollment target
20
Study locations

NCT07181161 is a Phase 1 study of Metastatic Prostate Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 177 participants, roughly in line with the 182-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target. The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07181161, a Phase 1 study of Metastatic Prostate Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
177 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.

Conditions Studied

Metastatic Prostate Cancer

Interventions

  • DRUG AZD9574
  • DRUG AZD0516

Study Locations (20)

Other

  • Research Site - Barretos
  • Research Site - Porto Alegre
  • Research Site - São Paulo
  • Research Site - Changsha
  • Research Site - Chengdu
  • Research Site - Wuhan
  • Research Site - Lyon
  • Research Site - Montpellier
  • Research Site - Saint-Herblain
  • Research Site - Suresnes

Michigan

  • Research Site - Ann Arbor
  • Research Site - Detroit

New York

  • Research Site - Buffalo
  • Research Site - New York

Arkansas

  • Research Site - Fayetteville

California

  • Research Site - Los Angeles

Massachusetts

  • Research Site - Boston

Rhode Island

  • Research Site - Providence

South Carolina

  • Research Site - Myrtle Beach

Trial Details

FieldValue
Enrollment Target 177 participants
Start Date 2025-10-01
Est. Completion 2029-01-18
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07181161

The ClinicalTrials.gov registry entry for NCT07181161 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 182-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which AZD9574 is the first listed.

NCT07181161 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Michigan, New York.

Frequently Asked Questions

What is clinical trial NCT07181161 about?

NCT07181161 is a clinical study titled "Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer". The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.

What is the current status of trial NCT07181161?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 177 participants. The study started on 2025-10-01. Estimated completion is 2029-01-18.

What conditions does trial NCT07181161 study?

This clinical trial studies the following conditions: Metastatic Prostate Cancer.

What interventions are being tested in trial NCT07181161?

The interventions under investigation include: AZD9574 (DRUG), AZD0516 (DRUG).

Who is sponsoring clinical trial NCT07181161?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07181161 being conducted?

This trial has 20 study locations across Arkansas, California, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Prostate Cancer

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.